Innoviva Inc (INVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Innoviva Inc (INVA) Stock Forecast
Analysts expect Innoviva (INVA) to earn $0.86 per share in the fiscal year ending Dec 31, 2026, on revenue of $434.53M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.40, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 1 | 20.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 151.2% and revenue estimates rise 9.4%.
- Fiscal year ending Dec 31, 2026
- $0.86
- EPS consensus, revenue $434.53M
- Fiscal year ending Dec 31, 2027
- $2.16
- EPS consensus, revenue $475.35M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.86 | $0.75 to $1.04 | 4 | $434.53M | $430.26M to $439.80M | 4 |
| Dec 31, 2027 | $2.16 | $1.87 to $2.37 | 5 | $475.35M | $423.70M to $514.60M | 5 |
Quarterly Estimates
The EPS consensus rises from $0.45 for the quarter ending Dec 31, 2026 to $0.49 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.45 | $0.34 to $0.56 | 7 | $113.93M | $104.45M to $121.91M | 7 |
| Mar 31, 2027 | $0.49 | $0.41 to $0.55 | 5 | $113.17M | $103.92M to $123.20M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 59.0% from $2.10.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.86 | $2.23 | $2.23 | $2.15 | $2.10 | -59.3% |
| Fiscal year ending Dec 31, 2027 | $2.16 | $2.26 | $2.26 | $2.33 | $2.33 | -7.4% |
| Quarter ending Mar 31, 2027 | $0.49 | $0.50 | $0.50 | $0.52 | $0.52 | -5.4% |
Frequently Asked Questions About INVA
What is the INVA stock forecast?
Consensus analyst estimates put Innoviva's EPS at $0.86 for the fiscal year ending Dec 31, 2026, on revenue of $434.53M. The consensus rating from 5 analysts is Buy.
How do analysts rate INVA stock?
Of 5 analysts covering Innoviva, 0 rate it Strong Buy, 4 Buy, 0 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from INVA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.86, with estimates from $0.75 to $1.04 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.16, with estimates from $1.87 to $2.37 from 5 analysts.
What revenue do analysts expect from Innoviva next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $434.53M, with estimates from $430.26M to $439.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $475.35M, with estimates from $423.70M to $514.60M.
How many analysts cover INVA?
5 analysts rate Innoviva stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
INVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors